302 related articles for article (PubMed ID: 38027003)
1. Post-marketing safety surveillance of sacituzumab govitecan: an observational, pharmacovigilance study leveraging FAERS database.
Liu W; Du Q; Guo Z; Ye X; Liu J
Front Pharmacol; 2023; 14():1283247. PubMed ID: 38027003
[No Abstract] [Full Text] [Related]
2. Post-marketing safety evaluation of lurbinectedin: a pharmacovigilance analysis based on the FAERS database.
Li Z; Guo C; Liu X; Qiu Z; Zhang R
Front Pharmacol; 2024; 15():1368763. PubMed ID: 38549677
[No Abstract] [Full Text] [Related]
3. Post-marketing safety concerns with abrocitinib: a real-world pharmacovigilance analysis of the FDA adverse event reporting system.
Zhu Z; Liu M; Zhang H; Zheng H; Li J
Expert Opin Drug Saf; 2024 May; ():1-8. PubMed ID: 38743462
[TBL] [Abstract][Full Text] [Related]
4. Assessing real-world safety concerns of Sacituzumab govitecan: a disproportionality analysis using spontaneous reports in the FDA adverse event reporting system.
Gui X; Zhao J; Ding L; Chai J; Lai H; Cai Y; Luo S; Zeng Y; Wu W; Chen H; Yao H; Wang Y
Front Oncol; 2023; 13():1276976. PubMed ID: 37869095
[TBL] [Abstract][Full Text] [Related]
5. A Real-World Disproportionality Analysis of Olaparib: Data Mining of the Public Version of FDA Adverse Event Reporting System.
Shu Y; He X; Liu Y; Wu P; Zhang Q
Clin Epidemiol; 2022; 14():789-802. PubMed ID: 35789689
[TBL] [Abstract][Full Text] [Related]
6. Post-Marketing Safety Concerns with Upadacitinib: A Disproportionality Analysis of the FDA Adverse Event Reporting system.
Wu XP; Lu XK; Wang ZT; Huang L; Cai RW; Yu HM; Li JY; Xiao J
Expert Opin Drug Saf; 2023; 22(10):975-984. PubMed ID: 37310063
[TBL] [Abstract][Full Text] [Related]
7. Adverse events in patients with advanced urothelial carcinoma treated with erdafitinib: a retrospective pharmacovigilance study.
Yuan T; Li F; Hou Y; Guo H
Front Pharmacol; 2023; 14():1266890. PubMed ID: 38074150
[No Abstract] [Full Text] [Related]
8. Adverse drug events associated with linezolid administration: a real-world pharmacovigilance study from 2004 to 2023 using the FAERS database.
Zou F; Cui Z; Lou S; Ou Y; Zhu C; Shu C; Chen J; Zhao R; Wu Z; Wang L; Chen Z; Chen H; Lan Y
Front Pharmacol; 2024; 15():1338902. PubMed ID: 38434706
[No Abstract] [Full Text] [Related]
9. A real-world pharmacovigilance study of axitinib: data mining of the public version of FDA adverse event reporting system.
Shu Y; Ding Y; Dai B; Zhang Q
Expert Opin Drug Saf; 2022 Apr; 21(4):563-572. PubMed ID: 34918584
[TBL] [Abstract][Full Text] [Related]
10. A real‑world pharmacovigilance study of FDA adverse event reporting system events for daratumumab.
Yun X; Zhou Y; Wu D; Liu Y; Wu Q
Expert Opin Drug Saf; 2024 May; 23(5):581-591. PubMed ID: 38600747
[TBL] [Abstract][Full Text] [Related]
11. A pharmacovigilance study of etoposide in the FDA adverse event reporting system (FAERS) database, what does the real world say?
Cui Z; Cheng F; Wang L; Zou F; Pan R; Tian Y; Zhang X; She J; Zhang Y; Yang X
Front Pharmacol; 2023; 14():1259908. PubMed ID: 37954852
[No Abstract] [Full Text] [Related]
12. A real-world pharmacovigilance study of FDA Adverse Event Reporting System (FAERS) events for venetoclax.
Yang Y; Shu Y; Chen G; Yin Y; Li F; Li J
PLoS One; 2022; 17(12):e0278725. PubMed ID: 36477747
[TBL] [Abstract][Full Text] [Related]
13. A real-world pharmacovigilance study of abaloparatide based on the FDA Adverse Event Reporting System (FAERS).
Shi X; Cheng Q; Zhao YZ; Zou SP; Sun MH
Osteoporos Int; 2023 Dec; 34(12):2047-2058. PubMed ID: 37594595
[TBL] [Abstract][Full Text] [Related]
14. A real-world disproportionality analysis of mesalazine data mining of the public version of FDA adverse event reporting system.
Liu M; Gu L; Zhang Y; Zhou H; Wang Y; Xu ZX
Front Pharmacol; 2024; 15():1290975. PubMed ID: 38357304
[No Abstract] [Full Text] [Related]
15. Post-Marketing Safety of Vemurafenib: A Real-World Pharmacovigilance Study of the FDA Adverse Event Reporting System.
Liu Y; Dong C; He X; Shu Y; Wu P; Zou J
J Pharm Pharm Sci; 2022; 25():377-390. PubMed ID: 36608646
[TBL] [Abstract][Full Text] [Related]
16. Safety evaluation of ceftazidime/avibactam based on FAERS database.
Zhang X; Jiang Y; Guo Y; Zhou W; Qiao W; Zhu H; Qi Z
Infection; 2024 Jun; ():. PubMed ID: 38842750
[TBL] [Abstract][Full Text] [Related]
17. Post-Marketing Safety Concerns With Secukinumab: A Disproportionality Analysis of the FDA Adverse Event Reporting System.
Shu Y; Ding Y; Liu Y; Wu P; He X; Zhang Q
Front Pharmacol; 2022; 13():862508. PubMed ID: 35754494
[No Abstract] [Full Text] [Related]
18. Psychiatric adverse events associated with GLP-1 receptor agonists: a real-world pharmacovigilance study based on the FDA Adverse Event Reporting System database.
Chen W; Cai P; Zou W; Fu Z
Front Endocrinol (Lausanne); 2024; 15():1330936. PubMed ID: 38390214
[TBL] [Abstract][Full Text] [Related]
19. Post-marketing safety of immunomodulatory drugs in multiple myeloma: A pharmacovigilance investigation based on the FDA adverse event reporting system.
Jiang T; Su H; Li Y; Wu Y; Ming Y; Li C; Fu R; Feng L; Li Z; Li L; Ni R; Liu Y
Front Pharmacol; 2022; 13():989032. PubMed ID: 36532784
[No Abstract] [Full Text] [Related]
20. Adverse events of guselkumab in the real world: emerging signals to target preventive strategies from the FDA adverse event reporting system.
Xiang DC; Chen W; Fu ZW; Wu XH; Gao P; Wu Y
Expert Opin Drug Saf; 2023; 22(10):943-955. PubMed ID: 37294594
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
